<div id="readability-page-1"><p>Codexis, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith from TD Cowen maintained a Hold rating on the stock and has a $2.00 price target.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Brendan Smith has given his Hold rating due to a combination of factors, including Codexis’ solid Q1 performance and the dependence on future execution. The company exceeded revenue expectations largely because of the Merck transfer-related contribution and reaffirmed its long-term targets, but much of the growth story still hinges on securing new CDMO and pharma partnerships and translating its ECO platform into recurring revenue.</p> <p>While management’s view of a sizable siRNA manufacturing opportunity and the potential differentiation from stereochemical control are encouraging, these remain early-stage validation and commercialization efforts. The upcoming TIDES presentation, planned GMP facility retrofit, and scale-up to half-kilo production are important milestones, yet the timing and magnitude of their impact are uncertain, supporting a neutral stance and an unchanged $2 price target.</p> </div>

CDXS

<p>Codexis maintains a Hold rating with a $2 price target, as analyst Brendan Smith from TD Cowen cites solid Q1 performance offset by execution risks. The company exceeded revenue expectations due to Merck contributions but relies on future partnerships and revenue from its ECO platform. Upcoming milestones, including the TIDES presentation and GMP facility retrofit, are crucial but their impact remains uncertain, justifying the neutral stance.</p>

Tip Ranks

Codexi

Merck

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares Global Healthcare

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Codexis: Neutral Stance Maintained as Execution Risks Offset Solid Q1; $2 Price Target Reaffirmed